The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Datsenko P.V.

Herzen Moscow Oncology Research Institute, Moscow, Russia, 125284

Lymphocyte lineage and hematological toxicity in Hodgkin’s lymphoma

Authors:

Datsenko P.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(6): 54‑60

Read: 4732 times


To cite this article:

Datsenko PV. Lymphocyte lineage and hematological toxicity in Hodgkin’s lymphoma. P.A. Herzen Journal of Oncology. 2016;5(6):54‑60. (In Russ.)
https://doi.org/10.17116/onkolog20165654-60

References:

  1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma — diagnosis and treatment. Lancet Oncol. 2004;5(1):19-26. doi:10.1016/S1470-2045(03)01320-2
  2. Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support Leuk. Lymphoma. 2008;49(8):1530-1536. doi:10.1080/10428190802210718
  3. Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137(6):545-552. doi:10.1111/j.1365-2141.2007.06598.x
  4. Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;8(Suppl.2):S63-S66. doi:10.3816/clm.2007.s.035
  5. Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol. 2000;11(9):1105-1114. doi:10.1023/a:1008301225839
  6. Franklin J, Diehl V. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol. 2002;13(Suppl.1):98-101. doi:10.1093/annonc/13.s1.98
  7. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(9):1734-1739. doi:10.1200/jco.2003.06.028
  8. Datsenko P, Pan'shin G, Dobrovol'skaya N, Sotnikov V, Mel'nik Yu. Four-year results of the new regime CEA / ABVD chemotherapy as part of an integrated treatment of advanced Hodgkin's disease (a poor prognostic group). Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii. 2005;(5). Available at: http:// vestnik.rncrr.ru/vestnik/v5/papers/dace_v5.htm (In Russ.)
  9. Datsenko P. Evolution programs combined treatment of Hodgkin's lymphoma. The new regime CEA/ABVD chemotherapy for Hodgkin's lymphoma [Evolyutsiya programm kombinirovannogo lecheniya limfomy Khodzhkina: Novyy rezhim khimioterapii CEA/ABVD pri limfome Khodzhkina]. Lambert Academic Publishing; 2012. (In Russ.)
  10. Datsenko P, Podol'skii P, Pan'shin G, Sotnikov V, Bozhenko V. Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity. Voprosy onkologii. 2010;56(5):571-575. (In Russ.)
  11. Ziepert M, Schmits R, Trümper L, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2008;19(4):752-762. doi:10.1093/annonc/mdm541
  12. Ivanov S. Prognosis of leukopenia at the early stages of radio- and chemotherapy for Hodgkin's disease. Voprosy onkologii. 2000;46(2):129-135. (In Russ.)
  13. Podol'skii P, Datsenko P, Pan'shin G, Sotnikov V, Bozhenko V. Risk factors hematological toxicity and multiparameter analysis of the laboratory data peripheral blood in Hodgkin's disease (Part 1): the statistic analysis. Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii. 2009;(9):15. (In Russ.)
  14. Datsenko P, Podol'skii P, Pan'shin G, Sotnikov V, Bozhenko V. Risk factors hematological toxicity and multiparameter analysis of the laboratory data peripheral blood in Hodgkin's disease (Part 2): the model of hematological toxicity. Vestnik Rossiiskogo nauchnogo tsentra rentgenoradiologii. 2009;(9):16. (In Russ.)
  15. Dvoretskii M. Benefit variation statistics [Posobie po variatsionnoi statistike]. Moscow; 1971. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.